While phenotypic (such as high-content) screens offer the opportunity for more complex disease-relevant and information-rich - readouts, combining them with an understanding of the mode of action of compounds is often crucial, both for compound optimization and drug approval. In this presentation, we will describe methods from the bio- and cheminformatics field for this purpose, as well as real-world applications.